Antibodies associated with neurologic syndromes
| Antigen location | Antibody | Characteristic neurologic syndrome |
|---|---|---|
| Intracellular | Anti-Yo (Purkinje cell cytoplasmic antibody type 1) | Paraneoplastic cerebellar degeneration |
| Anti-glutamic acid decarboxylase | Stiff person syndrome (progressive encephalomyelitis with rigidity, myoclonus) | |
| Anti-Hu (ANNA1) | Multiple, including paraneoplastic sensory neuropathy, paraneoplastic encephalomyelitis | |
| Anti-Ma2 | Encephalitis, limbic or upper brainstem | |
| Antiamphiphysin | Stiff person syndrome, paraneoplastic encephalomyelitis, limbic encephalitis | |
| Anti-CV2 (CRMP) | Multiple, including uveitis, optic neuritis, retinitis, paraneoplastic cerebellar degeneration | |
| Cell surface | Anti-NMDA receptor | Multistage syndrome, starting with limbic encephalitis and psychiatric changes followed by brainstem dysfunction |
| Anti-CASPR2 | Encephalitis or peripheral nerve hyperexcitability (if both, Morvan syndrome) | |
| Anti-LGI1 | Limbic encephalitis with faciobrachial dystonic seizures | |
| Anti-AMPA receptor | Limbic encephalitis, isolated psychiatric disturbances | |
| Anti-GABAB receptor | Limbic encephalitis, early prominent seizures | |
| Anti-glycine receptor | Stiff person syndrome |
AMPA = alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ANNA = antineuronal nuclear antibody; CASPR2 = contactin-associated protein 2; CRMP = collapsin-responsive mediated protein; GABAB = gamma-aminobutyric acid B; LGI1 = leucine-rich glioma-inactivated protein 1; NMDA = N-methyl-d-aspartate